[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"castration-resistant-prostatic-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:castration-resistant-prostatic-neoplasms":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100637594","impact-of-body-composition-on-dosimetry-of-177lu-psma-radioligand-therapy-100637594",false,"NCT07587814","Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy","Impact de la Composition Corporelle Sur la dosimétrie de la radiothérapie Interne vectorisée au 177Lu-PSMA","COCORIVO","Inclusion Criteria:\n\n* Signed informed consent\n* Male, age \\>= 18 years\n* Histologically confirmed prostatic adenocarcinoma with multidisciplinary decision for 177Lu-PSMA treatment\n* PSMA expression in tumor lesions confirmed by 68Ga-PSMA PET\u002FCT\n* Affiliated to or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Patient unable to understand the study or comply with study constraints (language barrier, psychological, geographic...)\n* Patient under legal protection (tutelle, curatelle, sauvegarde de justice)","MALE","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","COCORIVO is an interventional study evaluating the impact of body composition on dosimetry of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Body composition (muscle, lean, visceral fat, subcutaneous fat and total fat masses) will be automatically quantified from whole-body CT images acquired at 72-96h after 177Lu-PSMA injection using the Anthropometer3DNet software. Dosimetry will be evaluated for tumors and organs at risk (salivary glands, bone marrow, kidneys). The study also evaluates the impact of body composition on SUV quantification, the feasibility of single-timepoint dosimetry, and the evolution of body composition during treatment.",[27,28],"Carcinoma","Castration Resistant Prostatic Neoplasms",[30,31,32,33,34,35],"Lutetium-177","PSMA","Body composition","Dosimetry","Radioligand therapy","Prostate cancer","NOT_YET_RECRUITING","2026-05-11",{"date":39,"type":40},"2026-05-14","ACTUAL",{"date":42,"type":21},"2026-09",{"date":44,"type":21},"2029-06",{"name":46,"class":47},"Centre Henri Becquerel","OTHER","Castration-Resistant Prostatic Neoplasms"]